Background: The Virtual Reality Functional Capacity Assessment Tool (VRFCAT) is an "applied" game-based assessment that uses a multi-level functional task to assess instrumental activities of daily living (iADL). This study examines the feasibility, convergent validity, and predictive ability of the VRFCAT in a sample of inpatients with chronic schizophrenia.
Methods: Inpatients with a DSM-5 diagnosis of schizophrenia or schizoaffective disorder, completed the VRFCAT prior to discharge. The UPSA-B, SLOF, and PSP were administered, both at baseline and after four-weeks in the community. VRFCAT performance scores were compared to published data from the VRFCAT validation study.
Results: All 62 participants completed the VRFCAT. Compared to the performance of stable outpatients, participants performed 1.50 SDs below the VRFCAT mean adjusted total time (ATT) (Validation study: Mean T Score = 32.5, SD = 16.59) with more errors. The VRFCAT ATT T-score was significantly correlated with baseline UPSA-B total score (p = 0.005) and PSP Global score (p = 0.010). 34 participants completed the follow-up period (55%), and 28 were lost to follow-up. There were no statistically significant differences in VRFCAT scores between these two groups (all p > 0.29). The VRFCAT composite score at baseline was significantly associated with the UPSA-B total score (p = 0.010) and the PSP total score (p = 0.008) at four-weeks, as was the PSP Socially Useful Activities subscale score (p = 0.006).
Conclusion: The VRFCAT is a valid measure of iADLs in inpatients with chronic schizophrenia. The VRFCAT predicted instrumental functioning four-weeks post-discharge. Future studies should examine other moderators of measures of functional capacity pre-discharge, predicting function later in the community.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.schres.2020.07.001 | DOI Listing |
Background: Interventional trials in Alzheimer's Disease (AD) are increasingly targeting early disease stages. To optimize the likelihood of successful outcomes for these trials, there is an important need for tools capable of identifying individuals prone to exhibit clinical progression throughout the course of the trial. The Expanded Brief Assessment of Cognition (Expanded-BAC) and the Virtual Reality Functional Capacity Assessment Tool - Short List (VRFCAT-SLx) are two computerized tests assessing cognitive and functional abilities, respectively.
View Article and Find Full Text PDFAm J Psychiatry
December 2024
Bristol Myers Squibb, Boston (Horan, Sauder, Ramsay, Yohn, Paul, Brannan); University of Miami Miller School of Medicine, Miami (Harvey); Duke University School of Medicine, Durham (Keefe); Statistical Consultant, Chapel Hill (Davis).
Objective: Xanomeline and trospium chloride (formerly known as KarXT), a novel M/M muscarinic receptor agonist, demonstrated efficacy across phase 2 and 3 trials as monotherapy for the treatment of inpatients with acute schizophrenia on the Positive and Negative Syndrome Scale total score primary endpoint. In the phase 2 trial, xanomeline/trospium improved performance on a cognitive outcome measure in the subgroup of participants with clinically significant baseline cognitive impairment. The authors sought to confirm this finding using data from two phase 3 trials.
View Article and Find Full Text PDFJAMA Psychiatry
January 2025
Donders Institute for Brain, Cognition, and Behavior, Radboud University, Nijmegen, the Netherlands.
Schizophr Res Cogn
March 2025
Karuna Therapeutics, Boston, MA, United States of America.
Decentralized clinical trials are leading to rapid changes in assessment technology, including an expansion of interest in remote delivery. As technology changes, some of the updates include migration to fully cloud-based software and data management, with attendant differences in hardware, response modalities, and modifications in the level of tester engagement. It is rare to see systematic descriptions of the process of migration and upgrading of technology-related assessments.
View Article and Find Full Text PDFContemp Clin Trials Commun
October 2024
University of Miami Miller School of Medicine, Miami, FL, United States.
Background: Cognitive symptoms, among the core symptoms of schizophrenia, are associated with poor functional outcome and burden of illness. To date, there is no effective pharmacological treatment for these symptom clusters. Augmentation with psychostimulants has been proposed as a potential treatment option.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!